이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Kilitch Drugs (India) 관리
관리 기준 확인 2/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Mukund Mehta
최고 경영자
₹6.0m
총 보상
| CEO 급여 비율 | 100.0% |
| CEO 임기 | 32.1yrs |
| CEO 소유권 | 7.1% |
| 경영진 평균 재임 기간 | 데이터 없음 |
| 이사회 평균 재임 기간 | 8.2yrs |
최근 관리 업데이트
Recent updates
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05
Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings
Nov 17Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why
Sep 23These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors
May 05Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today
Apr 08These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 13Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?
Aug 20Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jul 16CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | ₹146m |
| Dec 31 2023 | n/a | n/a | ₹146m |
| Sep 30 2023 | n/a | n/a | ₹140m |
| Jun 30 2023 | n/a | n/a | ₹117m |
| Mar 31 2023 | ₹6m | ₹6m | ₹104m |
| Dec 31 2022 | n/a | n/a | ₹98m |
| Sep 30 2022 | n/a | n/a | ₹85m |
| Jun 30 2022 | n/a | n/a | ₹83m |
| Mar 31 2022 | ₹6m | ₹6m | ₹74m |
| Dec 31 2021 | n/a | n/a | ₹52m |
| Sep 30 2021 | n/a | n/a | ₹63m |
| Jun 30 2021 | n/a | n/a | ₹62m |
| Mar 31 2021 | ₹6m | n/a | ₹37m |
| Dec 31 2020 | n/a | n/a | ₹17m |
| Sep 30 2020 | n/a | n/a | ₹4m |
| Jun 30 2020 | n/a | n/a | -₹3m |
| Mar 31 2020 | ₹6m | n/a | ₹8m |
보상 대 시장: Mukund 의 총 보상 ($USD 71.86K )은 Indian 시장( $USD 38.49K ).
보상과 수익: Mukund 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Mukund Mehta (71 yo)
32.1yrs
테뉴어
₹6,000,000
보상
Mr. Mukund Prataprai Mehta, B.Com, LL B., serves as the Chairman and Managing Director at Kilitch Drugs (India) Limited and has been its Executive Director since May 12, 1992. Mr. Mehta served as the Compl...
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman & MD | 32.1yrs | ₹6.00m | 7.09% ₹ 382.6m | |
| Whole-time Director | 6.8yrs | ₹8.40m | 20.92% ₹ 1.1b | |
| Whole Time Director | 9.6yrs | ₹2.40m | 데이터 없음 | |
| Independent & Non Executive Director | 16yrs | ₹25.00k | 데이터 없음 | |
| Non-Executive Independent Director | 6.3yrs | ₹30.00k | 데이터 없음 | |
| Independent Non-Executive Director | 6yrs | ₹5.00k | 데이터 없음 |
8.2yrs
평균 재임 기간
65yo
평균 연령
경험이 풍부한 이사회: KILITCH 의 이사회는 경험(평균 재직 기간 8.2 년)으로 간주됩니다.